Medline financials
$34.98−0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 27 | Q1 '26 Mar 28 | Q4 '25 Dec 31 |
|---|---|---|---|
| Revenue | $7.68B | $7.35B | — |
| Gross profit | $2.21B | $1.84B | — |
| Gross margin | 28.8% | 25.0% | — |
| Operating income | $395.0M | $422.0M | — |
| Net income | $60.0M | $129.0M | — |
| Net margin | 0.8% | 1.8% | — |
| Diluted EPS | $0.07 | $0.16 | — |
| EBITDA | $651.0M | $676.0M | $0.00 |
| Operating cash flow | $715.0M | $412.0M | — |
| Free cash flow | $604.0M | $316.0M | — |
| Diluted shares | 860.9M | 824.8M | 809.7M |
Balance sheet
| Period end | Jun 27 | Mar 28 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $2.33B | $2.24B | $1.94B |
| Short-term investments | $350.0M | $0.00 | $0.00 |
| Total debt | $12.58B | $12.57B | $12.56B |
| Total assets | $39.35B | $39.01B | $38.48B |
| Total liabilities | $20.27B | $19.66B | $19.20B |
| Shareholders' equity | $19.08B | $19.35B | $19.29B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology